Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

Genetic Cohort Participants
Enrollmen Goal: 600

Genetic Registry Participants
Enrollment Goal: ~600

De Novo PD Participants
Enrollment Goal: 400

Control Participants
Enrollment Goal: 200

Subjects with SWEDD
Enrollment: 64

Prodromal Participants
Enrollment Goal: 100

Last Update: March 24, 2015


More about study cohorts >


Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.


Reform Movement and The Michael J. Fox Foundation Team Up for Study Investigating Genetic Mutations Common in Jews

Religious Action Center of Reform Judaism Director Rabbi Jonah Pesner: “This study provides an important opportunity to help potentially stamp out an insidious disease and reflects the Jewish imperative toward pikuach nefesh, the saving of a life.”

PPMI Expands to Include Individuals with GBA Mutation

PPMI will now be following individuals with a GBA mutation as part of the Genetic Cohort. In addition to being linked to Parkinson’s disease, GBA mutations can cause Gaucher disease. A GBA mutation is more common among certain populations, specifically those of Ashkenazi (Eastern European) Jewish descent. Read the full press release here.

PPMI at AD/PD 2015

PPMI is proud to be well-represented at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2015), which is being held March 18-22 in Nice, France. Find out when PPMI data will be presented.

Funding for Biomarkers Across Neurodegenerative Diseases

For the second year, PPMI is participating in the Biomarkers Across Neurodegenerative Diseases (BAND) program. The Alzheimer’s Association, Alzheimer’s Research UK, The Michael J. Fox Foundation and the Weston Brain Institute announce a collaborative Request for Applications to stimulate analyses across Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases.

2015 PPMI Study Update Call Series

Enrolled participants can take part in the PPMI Study Update Call Series. Calls take place on a quarterly basis and feature presentations and Q&A with leading researchers and study team members. View the 2015 call schedule.

Learn More